ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
5.19
+0.02 (0.39%)
Apr 24, 2025, 4:00 PM EDT - Market closed
ORIC Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for ORIC Pharmaceuticals stock have an average target of 18.43, with a low estimate of 14 and a high estimate of 22. The average target predicts an increase of 255.11% from the current stock price of 5.19.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 26, 2025.
Analyst Ratings
The average analyst rating for ORIC Pharmaceuticals stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 26, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $21 → $22 | Buy | Maintains | $21 → $22 | +323.89% | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +304.62% | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +304.62% | Feb 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +304.62% | Feb 21, 2025 |
Financial Forecast
Revenue This Year
n/a
from 56.64M
Revenue Next Year
n/a
EPS This Year
-2.06
from -1.83
EPS Next Year
-1.99
from -2.06
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 34.5M | 13.5M | ||
| Avg | n/a | 4.6M | 2.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 197.5% | ||
| Avg | - | - | -51.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.56 | -1.58 | -0.76 | ||
| Avg | -2.06 | -1.99 | -2.06 | ||
| Low | -2.23 | -2.93 | -3.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.